Yes, a patient can absolutely be on Ozempic and Jardiance without metformin.
Current guidelines explicitly state that SGLT2 inhibitors (like Jardiance/empagliflozin) and GLP-1 receptor agonists (like Ozempic/semaglutide) are recommended independent of metformin use, particularly for patients with established cardiovascular disease, heart failure, or chronic kidney disease 1.
When This Combination Is Recommended
The 2025 ADA Standards of Care make clear that for patients with:
- Established atherosclerotic cardiovascular disease (ASCVD)
- Heart failure
- Chronic kidney disease (CKD)
- High cardiovascular risk factors
Both an SGLT2 inhibitor and/or GLP-1 RA should be initiated "independent of A1C, with or without metformin use" 1. This represents a fundamental shift from older paradigms that positioned metformin as mandatory first-line therapy.
The Evidence Supporting This Approach
Cardiovascular and Renal Benefits
Both drug classes provide organ-protective effects beyond glucose lowering:
Semaglutide (Ozempic) has demonstrated cardiovascular benefits in the SUSTAIN 6 trial, reducing major adverse cardiovascular events 2, and recent evidence shows beneficial effects on CVD, mortality, and kidney outcomes in patients with CKD 1
Empagliflozin (Jardiance) has proven benefits in slowing CKD progression and improving cardiovascular outcomes in dedicated kidney outcomes trials 1
Combination Therapy Data
Recent research directly supports combining these agents:
A 2024 randomized trial of 120 patients showed that combination empagliflozin and semaglutide produced a substantial 10 mmHg reduction in 24-hour systolic blood pressure—significantly superior to either monotherapy. The combination also increased glycemic time in range from 72% to 91% without increasing hypoglycemia risk 3
An 18-month cohort study (SEMPA18) comparing the two agents found both effective, with empagliflozin showing more pronounced improvements in albuminuria and semaglutide trending toward greater weight loss 4
When Metformin Is NOT Required
The 2025 BMJ guideline clarifies that most medications can be used in combination (except GLP-1 RAs with tirzepatide due to similar mechanisms). The decision to avoid combining certain medications should be based on:
- Additive burden of administration
- Cumulative side effects (e.g., avoiding GLP-1 RAs if already experiencing GI side effects from metformin)
- Whether additive benefits are anticipated 5
Importantly, metformin provides no documented direct cardiovascular or kidney benefit 1, making it optional when organ-protective agents are prioritized.
Practical Algorithm for This Combination
Use Ozempic + Jardiance without metformin when:
Patient has established CVD, heart failure, or CKD → Both agents recommended regardless of metformin status 1
Patient cannot tolerate metformin → GI side effects (nausea, diarrhea) occur in >30% on metformin; no need to force continuation 2
Patient has eGFR 30-45 mL/min/1.73m² → Metformin dose must be reduced and becomes less effective; SGLT2i and GLP-1 RA remain beneficial 1
**Patient has eGFR <30 mL/min/1.73m²** → Metformin is contraindicated; both Ozempic and Jardiance can still be used (SGLT2i can be initiated if eGFR >20) 1
Patient prioritizes weight loss and BP reduction → The combination produces superior results compared to either agent alone 3
Important Caveats
Gastrointestinal Side Effects
Ozempic causes nausea (16-20%), vomiting (5-9%), and diarrhea (9%) during dose escalation 2. Starting both agents simultaneously may compound GI effects—consider staggering initiation.
Hypoglycemia Risk
When used together without sulfonylureas or insulin, hypoglycemia risk remains low. However, if the patient is on a sulfonylurea, documented symptomatic hypoglycemia occurred in 17-24% of patients on semaglutide 2. Reduce or discontinue sulfonylureas when starting this combination.
SGLT2i-Specific Concerns
Monitor for:
- Genital mycotic infections (more common with SGLT2i) 5
- Volume depletion in patients on diuretics
- Euglycemic DKA (rare but serious)
Dosing Considerations
- Ozempic: Start 0.25 mg weekly × 4 weeks, then 0.5 mg weekly; can increase to 1 mg weekly after ≥4 weeks 2
- Jardiance: Standard dose 10-25 mg daily
- Both can be initiated simultaneously in high-risk patients per current guidelines 1
Lower-Risk Patients
For patients without established CVD/CKD and with ≤3 cardiovascular risk factors, the 2025 BMJ guideline suggests against routine use of SGLT2i or GLP-1 RA, given little cardiovascular benefit but risk of harms (GI effects, genital infections) 5. In this population, metformin remains reasonable first-line therapy.
However, even in lower-risk patients, if metformin is not tolerated or contraindicated, the combination of Ozempic and Jardiance remains a valid option for glycemic control, particularly if weight loss is a priority.